guest column

Texas expert: Tapping into tech can help you overcome training challenges with your workforce

Lawrence Schwartz — CEO of Trivie, a tech-enabled workforce training solution — shares how employees forgetting training is one of the biggest challenges for businesses. Photo via Getty Images

Forgetting is the hobgoblin of businesses everywhere. Globally, more than $300 billion is spent annually by companies hoping to train their employees to do their jobs successfully and safely. Yet, learning professionals know that people will forget 80 percent or more of what they learned after 30 to 90 days unless it's reinforced.

It's a human biology problem — people forget. However, if that were the only issue, it would have been solved long ago. Instead, it's a holistic issue that includes how people learn and forget, how people engage with training, and how knowledge gaps are identified and addressed across entire organizations.

How do we get people to remember what we need them to know to do their job more effectively? And how do we do it without it taking up so much of their time that training becomes impossibly expensive?

Therein lies the problem. Neuroscientists have done extensive research on how the brain remembers things long-term, and it's not what most people think.

We've grown up in a culture of cramming. Review the content over and over right before a test, take the test, pass it, and you're done. Check the box. Unfortunately, your brain is done with that material too, and over time, it will purge itself of that information unless you do something about it.

The act of forgetting allows our brains to strengthen their neurological pathways to help us remember. This is called "retrieval practice" and according to Dr. Henry Roediger, one of the authors of the book, Make It Stick: "Retrieval practice via quizzes spaced out over time helps to consolidate knowledge and keep it on employees' 'mental fingertips,' so it is easy to access when needed." In essence, you re-introduce something learned so that the brain "recalls" it, and if done enough over a certain period, it is more likely that people will remember this information longer.

With today's technology, we can automate spaced repetition. Artificial intelligence can predict when people will forget and proactively nudge employees to avoid creating knowledge gaps across organizations. Delivering information in a personalized way, such that every learner has their own proficiency map, enables knowledge retention with very little time expenditure.

It's human nature that when someone knows more, they are more confident in their abilities. This translates to better performance across nearly all use cases within a business. Top salespeople know their product like the back of their hands to identify solutions for customers quickly. The best customer service teams don't just reference knowledge bases; they are familiar with the product, processes, or services that allow them to be responsive and think holistically about issues. The safest work environments are a product of employees knowing what they need to do to keep themselves, and each other, safe. Knowledge retention powers high-performing people and organizations.

Forgetting can never be eliminated. Rather, businesses that leverage forgetting as opportunities to strengthen their people's knowledge will create a culture of continuous learning. Employees will feel more empowered and confident. Knowledge silos will be broken down, and the analog ways that knowledge was retained across peer interactions will become digital. An open network of knowledge will emerge and supplement our brains, making what was once a weakness in human biology, forgetting, an opportunity to remember.

------

Lawrence Schwartz is the co-founder and CEO of Texas-based Trivie.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted